Research and Markets: Renal Cell Carcinoma (RCC) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/0a42a1/renal_cell_carcino) has announced the addition of GlobalData's new report "Renal Cell Carcinoma (RCC) Therapeutics - Pipeline Assessment and Market Forecasts to 2017" to their offering.

Renal Cell Carcinoma (RCC) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 is an essential source of information and analysis on the global renal cell carcinoma therapeutics market. The report identifies the key trends shaping and driving the global renal cell carcinoma therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global renal cell carcinoma therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

RCC Therapeutics Market is Forecast to Show High Growth until 2017

The authors estimate that the global renal cell carcinoma (RCC) market was valued at $1.3 billion in 2009 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 13.9% over the next eight years, to reach $3.8 billion by 2017. This high growth forecast is primarily attributed to population growth and high diagnosis rates. In addition, the RCC market will continue to be driven by the strong pipeline landscape of first-in-class drugs with better survival rates, safety and efficacy profiles. Unmet Need Continues to Challenge Pipeline Drugs

The authors research indicates that the prevailing pipeline landscape is strong, with companies and institutions working on products that seem satisfy the unmet needs of the RCC market. The current market provides scope for pipeline drugs that are strong in terms of overall survival rates, efficacy and safety. As patients become more aware of the latest technological developments, the key factors that will drive acceptance will be improved efficacy, tolerability and safety profiles as well as market penetration of pipeline products. As the current products in the market do not serve the unmet needs there will continue to be opportunities for stronger pipeline candidates. The pipeline products constitute first-in-class drugs with proven superiority in terms of therapeutic performance. Hence, the existing market leaders will face significant challenges to their market shares.

Key Topics Covered:

  • 1.1 List of Tables
  • 1.2 List of Figures
  • 2 Renal Cell Carcinoma Therapeutics: Introduction
  • 3 Renal Cell Carcinoma Therapeutics: Market Characterization
  • 4 Renal Cell Carcinoma Therapeutics: Competitive Assessment
  • 5 Renal Cell Carcinoma Therapeutics: Pipeline Assessment
  • 6 Renal Cell Carcinoma Therapeutics: Implications for Future Market Competition
  • 7 Renal Cell Carcinoma Therapeutics: Future Players in the RCC Therapeutics Market
  • 8 Renal Cell Carcinoma Therapeutics: Appendix

Companies Mentioned:

  • Pfizer Inc.
  • Novartis AG
  • WILEX AG
  • Antigenics, Inc
  • Sanofi-Aventis

For more information visit http://www.researchandmarkets.com/research/0a42a1/renal_cell_carcino

Contacts

Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Contacts

Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716